Advertisement

Topics

Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of Imvamune Smallpox Vaccine

00:02 EST 6 Feb 2018 | Drugs.com

COPENHAGEN, Denmark, February 6, 2018 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced positive results from a Phase 3 pivotal study of its investigational, non-replicating smallpox vaccine, Imvamune. The study achieved both of its...

Original Article: Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of Imvamune Smallpox Vaccine

NEXT ARTICLE

More From BioPortfolio on "Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of Imvamune Smallpox Vaccine"

Advertisement
Quick Search
Advertisement
Advertisement